Sunday, September 24, 2023
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Professor of Medical Oncology
Institut Gustave Roussy
Villejuif, France
Research Nurse
Institut Gustave Roussy
Villejuif, France
Associate Professor of Pathology
Department of Oncology and Hemato-Oncology
University of Milan
Director, Division of Pathology
IEO, European Institute of Oncology IRCCS
Milan, Italy
Full Professor
Department of Obstetrics and Gynecology
Director, Breast Center
LMU University Hospital
Munich, Germany
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.50 ABIM MOC points
This educational activity is intended for an international audience of non-US oncology specialists, pathologists, and obstetricians and gynecologists in Europe.
The goal of this activity is for learners to better able to define human epidermal growth factor receptor 2 (HER2)-low, describe the latest recommendations for HER2 testing, and discuss the latest clinical trial data investigating novel therapies for the treatment of metastatic HER2-low breast cancer.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Professor of Medical Oncology
Institut Gustave Roussy
Villejuif, France
Research Nurse
Institut Gustave Roussy
Villejuif, France
Associate Professor of Pathology
Department of Oncology and Hemato-Oncology
University of Milan
Director, Division of Pathology
IEO, European Institute of Oncology IRCCS
Milan, Italy
Full Professor
Department of Obstetrics and Gynecology
Director, Breast Center
LMU University Hospital
Munich, Germany
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Developed through a partnership between Medscape and Gustave Roussy.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 8/4/2023
Valid for credit through: 8/4/2024, 11:59 PM EST
processing....
Download the pdf.
| « Return to: European Centers of Excellence: Perspectives on HER2-Low Breast Cancer |
